NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.

Wang, Limin Tang, Wei Yang, Shouhui He, Peijun Wang, Jian Gaedcke, Jochen Ströbel, Philipp Azizian, Azadeh Ried, Thomas Gaida, Matthias M Yfantis, Harris G Lee, Dong H Lal, Ashish Van den Eynde, Benoît [UCL] Alexander, H Richard Ghadimi, B Michael Hanna, Nader Hussain, S Perwez et al.[show all]

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is refractory to available treatments. Delineating the regulatory mechanisms of metabolic reprogramming, a key event in pancreatic cancer progression, may identify candidate targets with potential therapeutic significance. We hypothesized that inflammatory signaling pathways regulate metabolic adaptations in pancreatic cancer. Metabolic profiling of tumors from PDAC patients with a high- (>median, n = 31) and low-NOS2 (inducible nitric oxide synthase;